COMPAZINE
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE is an oral extended-release small molecule antipsychotic approved by GSK in 1999. The drug mechanism of action and specific indications are not detailed in available data, but it represents a legacy psychiatric agent in capsule formulation. It is used for patients requiring sustained dopamine modulation.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100); minimal current job market activity suggests a contracted team focused on legacy management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMPAZINE offers limited career growth opportunities; the zero linked job openings and approaching LOE suggest this is a maintenance-focused role rather than a launch or growth platform. Professionals assigned here should expect a smaller team and emphasis on cost management, reimbursement retention, and generic transition planning.
Brand ManagerProduct Manager
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.